News | January 03, 2024
Glenmark to launch biosimilar of anti-diabetic drug Liraglutide in India
Liraglutide belongs to the class of glucagon like peptide 1 receptor agonist (GLP?1 RA) drugs
Liraglutide belongs to the class of glucagon like peptide 1 receptor agonist (GLP?1 RA) drugs
Vyleesi is the first and only as-needed treatment approved by the Food and Drug Administration (FDA) for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD)
Roche will pay a purchase price of USD 295 million and an additional payment of up to USD 55 million
The unit’s contribution to the company's revenue US$3.85 million in the last fiscal year
Marks remarkable acceleration in innovation using AI technology
Karkinos Healthcare has demonstrated exceptional dedication to privacy, setting a commendable example for businesses navigating the complexities of the digital landscape
This combination aims to offer an effective tool to manage symptoms of nausea and vomiting during pregnancy
Elpiscience will receive up to US $37 million, including the upfront payment and license option fees
The product is expected to be launched in December 2023
Transaction delivers KarXT, a first-in-class M1/ M4 muscarinic receptor agonist with differentiated efficacy and safety
Subscribe To Our Newsletter & Stay Updated
